Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials

Angiogenesis/Protein Tyrosine Kinase

Chemical Structure Cat. No. Product Name CAS No.
123C4 Chemical Structure
BCP44969 123C4 2034159-30-1
123C4 is a novel, potent, and selective agonist of the tyrosine kinase EphA4 receptor.
Amphiregulin, Human Recombinant Chemical Structure
BCP44759 Amphiregulin, Human Recombinant 117147-70-3
Amphiregulin is an EGF related growth factor that signals through the EGF/TGF-a receptor, and stimulates growth of keratinocytes, epithelial cells and some fibroblasts.
Almonertinib hydrochloride Chemical Structure
BCP44623 Almonertinib hydrochloride 2134096-03-8
Almonertinib hydrochloride is an orally available and third-Generation inhibitor of epidermal growth factor receptor (EGFR)-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.
Belzutifan Chemical Structure
BCP32143 Belzutifan 1672668-24-4
Belzutifan is an orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity.
AZD-7451 Chemical Structure
BCP44112 AZD-7451 1079274-94-4
AZD7451 is a tropomyosin receptor kinase (TRK) inhibitor with potential antineoplastic activity
RN983 Chemical Structure
BCP44110 RN983 1423129-83-2
RN983 is a selective BTK enzyme inhibitor.
PF-06459988 Chemical Structure
BCP44108 PF-06459988 1428774-45-1
PF-06459988 is an orally available, small molecule, third-generation, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant (EGFRm) forms with potential antineoplastic activity.
c-Fms-IN-12 Chemical Structure
BCP44099 c-Fms-IN-12 1313407-95-2
c-Fms-IN-12 is a c-Fms inhibitor.
BIIB068 Chemical Structure
BCP44097 BIIB068 1798787-27-5
BIIB068 is a potent, selective, reversible and orally active BTK inhibitor.
JNJ-38877605 Chemical Structure
BCP44121 JNJ-38877605 943540-74-7
JNJ-38877618 is a hepatocyte growth factor receptor (HGFR; MET; c-Met) inhibitor potentially for the treatment of solid tumours.
123下一页末页共 817 条记录 1 / 82 页